Pushing the entire pharmaceutical supply chain toward sustainability
In an industry long defined by scientific precision rather than ecological conscience, WuXi Biologics has staked a claim that the two need not be separate pursuits. The Shanghai-based contract drug manufacturer earned the CDP's highest 'A' ratings across Climate Change, Water Security, and Supplier Engagement in 2025 — a triple distinction signaling that large-scale pharmaceutical manufacturing can be reimagined around planetary boundaries. The recognition arrives at a moment when environmental credibility is becoming not merely a moral posture but a competitive one, suggesting the broader sector may be approaching an inflection point.
- The pharmaceutical industry faces mounting pressure to reconcile its resource-intensive manufacturing processes with a world demanding corporate accountability on climate and water — WuXi is answering that pressure with measurable commitments rather than aspirational language.
- A net-zero target validated by the Science Based Targets initiative and a 30% reduction in water consumption intensity by end-2025 give WuXi's pledges a credibility that distinguishes them from the greenwashing that plagues corporate sustainability discourse.
- The company's Ireland facility running on 100% renewable electricity and its three consecutive 'A' ratings for Water Security represent concrete proof points that its roadmap is moving from strategy to execution.
- By earning a Supplier Engagement 'A' and tracking Scope 3 emissions across its supply chain, WuXi is extending its environmental ambitions outward — attempting to reshape the practices of the entire pharmaceutical manufacturing ecosystem, not just its own operations.
- With an MSCI AAA rating, EcoVadis Platinum Medal, and five consecutive years as a Sustainalytics top performer, WuXi is assembling a portfolio of third-party validations that position green credentials as a genuine commercial differentiator in biologics manufacturing.
WuXi Biologics, the Shanghai-based contract manufacturer of biological drugs, has received the CDP's highest 'A' grade for both Climate Change and Water Security in 2025 — the second consecutive year it has achieved this dual distinction. The CDP, a nonprofit that benchmarks corporate environmental performance, places WuXi among the world's most transparent and ambitious companies on these fronts.
The climate rating is anchored by a net-zero commitment across WuXi's entire value chain by 2050, a target validated by the Science Based Targets initiative to ensure it reflects genuine scientific requirements rather than convenient ambition. The company has translated that commitment into operational changes — tightening energy use, redesigning manufacturing processes, and transitioning to renewables. Its biologics facility in Ireland now runs entirely on renewable electricity.
On water, WuXi has held the CDP's top rating for three consecutive years. Its formal water management system aligns with the UN's Sustainable Development Goal 6, and the company has committed to reducing water consumption intensity by 30 percent against 2019 levels by the close of 2025. This year it launched a Water Excellence Stewardship program addressing governance, water balance, quality, and access across its global operations.
A third 'A' rating — for Supplier Engagement — signals that WuXi's ambitions extend beyond its own facilities. The company tracks Scope 3 emissions from its vendors and has built a formal sustainable supply chain management system, effectively attempting to pull its broader network of partners toward climate-responsible practices.
CEO Chris Chen framed the recognition as confirmation of WuXi's identity as a 'green biologics' manufacturer — a positioning that carries growing commercial weight as customers increasingly factor environmental risk management into procurement decisions. The company's sustainability credentials span multiple third-party frameworks, including an MSCI AAA rating, a Platinum Medal from EcoVadis, and five consecutive years as a Sustainalytics top performer in its industry.
Operating across China, the United States, Ireland, Germany, and Singapore with more than 12,000 employees, WuXi is treating sustainability not as a compliance obligation but as foundational infrastructure for long-term growth — a wager that the pharmaceutical sector's environmental reckoning is not approaching, but already underway.
WuXi Biologics, a Shanghai-based contract manufacturer of biological drugs, has earned the highest environmental ratings available from the CDP—a nonprofit that tracks corporate climate and water performance—for the second consecutive year. The company received an 'A' grade for both Climate Change and Water Security in 2025, a distinction that places it among the world's most transparent and ambitious companies on these fronts.
The climate recognition reflects WuXi's commitment to reach net-zero emissions across its entire value chain by 2050. That target has been validated by the Science Based Targets initiative, a credibility checkpoint that ensures corporate climate pledges align with what climate science actually demands. To get there, the company has mapped out a detailed roadmap and begun executing concrete steps: tightening energy use, redesigning manufacturing processes, and shifting to renewable power. The most visible proof point is its biologics facility in Ireland, which now runs entirely on renewable electricity.
On water, WuXi has now made the CDP's 'A' list three years running. The company has built a formal water management system aligned with the United Nations' Sustainable Development Goal 6, which focuses on clean water and sanitation. It has committed to cutting water consumption intensity by 30 percent by the end of 2025 compared to 2019 levels. This year, the company launched a Water Excellence Stewardship program that addresses water governance, water balance, water quality, and access to safe water and sanitation across its operations.
WuXi also earned an 'A' rating in a third CDP category: Supplier Engagement. This measures how well a company pushes its vendors and partners to adopt climate-friendly practices. WuXi has built a formal sustainable supply chain management system, tracks emissions from its suppliers (known as Scope 3 emissions), and monitors progress against targets. The message is clear: the company is not just cleaning up its own house but trying to drag the entire pharmaceutical supply chain toward sustainability.
Chris Chen, the company's chief executive and chair of its ESG committee, framed the recognition as validation of WuXi's identity as a "green biologics" manufacturer—a positioning that matters in an industry where environmental credentials are becoming a selling point. He said the ratings strengthen the company's resolve to push the sector toward more responsible practices.
WuXi's environmental credentials extend beyond the CDP. It holds an MSCI AAA rating, the highest available. It earned a Platinum Medal from EcoVadis, another sustainability rater. It appears in the Dow Jones Sustainability Indices and the FTSE4Good Index Series. Sustainalytics, a third-party ESG analyst, has rated it as a top performer in its industry for five consecutive years. The company is also a signatory to the United Nations Global Compact and participates in the Pharmaceutical Supply Chain Initiative, both of which commit members to advancing sustainability.
WuXi Biologics operates across five countries—China, the United States, Ireland, Germany, and Singapore—with more than 12,000 employees. As of mid-2025, it was supporting 864 integrated client projects, including 24 in commercial manufacturing. The company frames sustainability not as a compliance burden but as foundational to long-term growth, a bet that customers increasingly want to work with manufacturers that can prove they are managing environmental risk.
Notable Quotes
These ratings strengthen our resolve as a global leader in green biologics to drive the industry toward a more responsible and sustainable future.— Chris Chen, CEO and ESG Committee Chair, WuXi Biologics
The Hearth Conversation Another angle on the story
What does it actually mean for a manufacturing company to get an 'A' from CDP? Is that just a marketing badge?
It's more rigorous than that. CDP asks companies to disclose detailed data on their emissions, water use, supply chain risks, and climate strategy. They verify it. An 'A' means the company is in the top tier globally on transparency and ambition—not just saying they care, but showing the numbers and the plan.
So WuXi is making biologics, which I assume uses a lot of water and energy. How do you actually cut water use by 30 percent in that kind of operation?
You redesign processes, install more efficient equipment, recycle water where you can, and monitor consumption constantly. It's not magic, but it requires real investment and discipline. The fact that they've done it three years in a row suggests it's not a one-time win.
The Ireland facility running on 100 percent renewable electricity—is that unusual in pharma manufacturing?
It's becoming less unusual, but it's still ahead of the curve. Pharma manufacturing is energy-intensive. Getting to 100 percent renewable at even one facility signals serious commitment. It also helps them sell to customers who care about their own carbon footprint.
Why does supplier engagement matter so much here?
Because a company's direct emissions are only part of the story. If you're buying materials and services from suppliers that are carbon-heavy, you're responsible for that too. WuXi is saying it's not enough to clean up your own operations—you have to push your entire network to do the same.
Is this the kind of thing that actually moves markets, or is it mostly for ESG investors?
Both. ESG investors use these ratings to decide where to put money. But increasingly, pharmaceutical companies—WuXi's customers—are being asked by their own investors and regulators to prove their supply chains are sustainable. So WuXi's ratings become a competitive advantage in winning contracts.